Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 58 results.
User Information
Export Records
  1. 1.   Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer
  2. Koutros, S.; Andreotti, G.; Berndt, S. I.; Barry, K. H.; Lubin, J. H.; Hoppin, J. A.; Kamel, F.; Sandler, D. P.; Burdette, L. A.; Yuenger, J.; Yeager, M.; Alavanja, M. C. R.; Freeman, L. E. B.
  3. Pharmacogenetics and Genomics. 2011, Oct; 21(10): 615-623.
  1. 2.   Population pharmacokinetic analysis of sorafenib in patients with solid tumours
  2. Jain, L.; Woo, S.; Gardner, E. R.; Dahut, W. L.; Kohn, E. C.; Kummar, S.; Mould, D. R.; Giaccone, G.; Yarchoan, R.; Venitz, J.; Figg, W. D.
  3. British Journal of Clinical Pharmacology. 2011, Aug; 72(2): 294-305.
  1. 3.   Isolation and Characterization of the CYP2D6 Gene in Felidae with Comparison to Other Mammals
  2. Schenekar, T.; Winkler, K. A.; Troyer, J. L.; Weiss, S.
  3. Journal of Molecular Evolution. 2011, Feb; 72(2): 222-231.
  1. 4.   Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1 alpha Expression in an AhR-Independent Fashion
  2. Terzuoli, E.; Puppo, M.; Rapisarda, A.; Uranchimeg, B.; Cao, L. A.; Burger, A. M.; Ziche, M.; Melillo, G.
  3. Cancer Research. 2010, Sep 1; 70(17): 6837-6848.
  1. 5.   How Does the Reductase Help To Regulate the Catalytic Cycle of Cytochrome P450 3A4 Using the Conserved Water Channel?
  2. Fishelovitch, D.; Shaik, S.; Wolfson, H. J.; Nussinov, R.
  3. Journal of Physical Chemistry B. 2010, May; 114(17): 5964-5970.
  1. 6.   Theoretical Characterization of Substrate Access/Exit Channels in the Human Cytochrome P450 3A4 Enzyme: Involvement of Phenylalanine Residues in the Gating Mechanism
  2. Fishelovitch, D.; Shaik, S.; Wolfson, H. J.; Nussinov, R.
  3. Journal of Physical Chemistry B. 2009 113(39): 13018-13025.
  1. 7.   Aryl Hydrocarbon Receptor Expression Is Associated with a Family History of Upper Gastrointestinal Tract Cancer in a High-Risk Population Exposed to Aromatic Hydrocarbons
  2. Roth, M. J.; Wei, W. Q.; Baer, J.; Abnet, C. C.; Wang, G. Q.; Sternberg, L. R.; Warner, A. C.; Johnson, L. L.; Lu, N.; Giffen, C. A.; Dawsey, S. M.; Qiao, Y. L.; Cherry, J.
  3. Cancer Epidemiology Biomarkers & Prevention. 2009 18(9): 2391-2396.
  1. 8.   Efavirenz Induces CYP2B6-Mediated Hydroxylation of Bupropion in Healthy Subjects
  2. Robertson, S. M.; Maldarelli, F.; Natarajan, V.; Formentini, E.; Alfaro, R. M.; Penzak, S. R.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2008 49(5): 513-519.
  1. 9.   A novel synthetic analogue of a constituent of Isodon excisus inhibits transcription of CYP1A1,-1A2 and-1B1 by preventing activation of the aryl hydrocarbon receptor
  2. Sienkiewicz, P.; Ciolino, H. P.; Leslie, B. J.; Hergenrother, P. J.; Singletary, K.; Yeh, G. C.
  3. Carcinogenesis. 2007, May; 28(5): 1052-1057.
  1. 10.   Modular architecture of protein structures and allosteric communications: potential implications for signaling proteins and regulatory linkages
  2. del Sol, A.; Arauzo-Bravo, M. J.; Moya, D. A.; Nussinov, R.
  3. Genome Biology. 2007 8(5):
  1. 11.   The chemical defensome: Environmental sensing and response genes in the Strongylocentrotus purpuratus genome
  2. Goldstone, J. V.; Hamdoun, A.; Cole, B. J.; Howard-Ashby, M.; Nebert, D. W.; Scally, M.; Dean, M.; Epel, D.; Hahn, M. E.; Stegeman, J. J.
  3. Developmental Biology. 2006, Dec; 300(1): 366-384.
  1. 12.   Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats
  2. Moon, K. H.; Hood, B. L.; Kim, B. J.; Hardwick, J. P.; Conrads, T. P.; Veenstra, T. D.; Song, B. Y. J.
  3. Hepatology. 2006, Nov; 44(5): 1218-1230.
  1. 13.   Modeling dioxygen binding to the non-heme iron-containing enzymes
  2. Nemukhin, A. V.; Grigorenko, B. L.; Topol, I. A.; Burt, S. K.
  3. International Journal of Quantum Chemistry. 2006, Aug; 106(10): 2184-2190.
  1. 14.   Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450
  2. Inami, K.; Nims, R. W.; Srinivasan, A.; Citro, M. L.; Saavedra, J. E.; Cederbaum, A. I.; Keefer, L. K.
  3. Nitric Oxide-Biology and Chemistry. 2006, Jun; 14(4): 309-315.
  1. 15.   On the nature of oxoiron (IV) intermediate in dioxygen activation by non-heme enzymes
  2. Nemukhin, A. V.; Topol, I. A.; Cachau, R. E.; Burt, S. K.
  3. Theoretical Chemistry Accounts. 2006, MAY; 115(5): 348-353.
  1. 16.   Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort
  2. Robertson, S. M.; Formentini, E.; Alfaro, R. M.; Natarajan, V.; Falloon, J.; Penzak, S. R.
  3. British Journal of Clinical Pharmacology. 2006, Apr; 61(4): 379-388.
  1. 17.   Transcriptomic analysis of an in vitro murine model of ovarian carcinoma: Functional similarity to the human disease and identification of prospective tumoral markers and targets
  2. Urzua, U.; Roby, K. F.; Gangi, L. M.; Cherry, J. M.; Powell, J. I.; Munroe, D. J.
  3. Journal of Cellular Physiology. 2006, MAR; 206(3): 594-602.
  1. 18.   Prednisolone pharmacokinetics in the presence and absence of Ritonavir after oral prednisone administration to healthy volunteers
  2. Penzak, S. R.; Fomnentini, E.; Alfaro, R. M.; Long, M.; Natarajan, V.; Kovacs, J.
  3. Jaids-Journal of Acquired Immune Deficiency Syndromes. 2005, DEC 15; 40(5): 573-580.
  1. 19.   Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
  2. Lepper, E. R.; Baker, S. D.; Permenter, M.; Ries, N.; van Schaik, R. H. N.; Schenk, P. W.; Price, D. K.; Ahn, D.; Smith, N. F.; Cusatis, G.; Ingersoll, R. G.; Bates, S. E.; Mathijssen, R. H. J.; Verweij, J.; Figg, W. D.; Sparreboom, A.
  3. Clinical Cancer Research. 2005, OCT 15; 11(20): 7398-7404.
  1. 20.   Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2
  2. Cheung, C.; Ma, X. C.; Krausz, K. W.; Kimura, S.; Feigenbaum, L.; Dalton, T. P.; Nebert, D. W.; Idle, J. R.; Gonzalez, F. J.
  3. Chemical Research in Toxicology. 2005, SEP; 18(9): 1471-1478.
  1. 21.   CYP1A1 Val(462) and NQO1 Ser(187) polymorphisms, cigarette use, and risk for colorectal adenoma
  2. Hou, L. F.; Chatterjee, N.; Huang, W. Y.; Baccarelli, A.; Yadavalli, S.; Yeager, M.; Bresalier, R. S.; Chanock, S. J.; Caporaso, N. E.; Ji, B. T.; Weissfeld, J. L.; Hayes, R. B.
  3. Carcinogenesis. 2005, JUN; 26(6): 1122-1128.
  1. 22.   The CYP2E1-humanized transgenic mouse: Role of CYP2E1 in acetaminophen hepatotoxicity
  2. Cheung, C.; Yu, A. M.; Ward, J. M.; Krausz, K. W.; Akiyama, T. E.; Feigenbaum, L.; Gonzalez, F. J.
  3. Drug Metabolism and Disposition. 2005, MAR; 33(3): 449-457.
  1. 23.   The nitric oxide prodrug, V-PYRRO/NO, protects against cadmium toxicity and apoptosis at the cellular level
  2. Qu, W.; Liu, J.; Fuquay, R.; Shimoda, R.; Sakurai, T.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P.
  3. Nitric Oxide-Biology and Chemistry. 2005, MAR; 12(2): 114-120.
  1. 24.   Fluorinated 2-(4-amino-3-methylphenyl) benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells
  2. Brantley, E.; Trapani, V.; Alley, M. C.; Hose, C. D.; Bradshaw, T. D.; Stevens, M. F. G.; Sausville, E. A.; Stinson, S. F.
  3. Drug Metabolism and Disposition. 2004, DEC; 32(12): 1392-1401.
  1. 25.   Enhanced acetaminophen toxicity by activation of the pregnane X receptor
  2. Guo, G. L.; Moffit, J. S.; Ward, J. M.; Aleksunes, L. A.; Slitt, A. L.; Kliewer, S. A.; Manautou, J. E.; Gonzalez, F. J.
  3. Toxicological Sciences. 2004, DEC; 82(2): 374-380.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel